HUMANIGEN, INC : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01. Other Events.

On July 12, 2022, Humanigen, Inc. (the "Company") issued a press release announcing preliminary top-line data received from the National Institutes of Health ("NIH") Phase 2/3 trial of lenzilumab (referred to as ACTIV-5/BET-B) in patients hospitalized with COVID-19. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

 (d) Exhibits




Exhibit
  No.       Description

99.1          Press release, dated July 12, 2022

104         Cover Page Interactive Data File (embedded within Inline XBRL document).

© Edgar Online, source Glimpses